Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCs) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies
- Citation:
- Hammad, R. W., R. A. B. Sanad, nevine shawky abdelmalk, R. Latif, and F. A. Torad, "Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCs) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies", AAPS PharmSciTech, vol. 19, number 8, pp. 3791-3808, 2018.